Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06013956 · ClinicalTrials.gov registry record · Phase 4
Personalized Real-Time DBS and PD Mechanisms
A Phase 4 study of Parkinson Disease, sponsored by David Escobar.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06013956: Recruiting Phase 4 study of Parkinson Disease, sponsored by David Escobar.
NCT06013956 is a Phase 4 study of Parkinson Disease that is actively recruiting participants, run by David Escobar. The registered enrollment target is 25 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06013956, a Phase 4 study of Parkinson Disease, is actively recruiting participants, sponsored by David Escobar.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
A prospective cohort of patients scheduled to undergo deep brain stimulation (DBS) implantation surgery for the treatment of Parkinson's disease as per standard of care will be invited to participate in this study. This mechanistic study is aimed at better understanding the role of basal ganglia beta band (11-35 Hz) oscillations and resonance in the manifestation of Parkinson's disease (PD) motor signs using closed-loop electrical neurostimulation, levodopa medication, and computational modeling. The ultimate goal of this study is to inform the development of closed-loop neuromodulation technology that can be programmed and adjusted in real time based on patient-specific neural activity.
Primary Outcome
The finger tapping speed will be measured with an inertial measuring unit. The relationship (slope/effect) between this kinematic variable (response variable) and the mean amplitude of beta (11-35 Hz) oscillations (predictor physiological variable) will be estimated via linear mixed-effects (LME) models. The LME models will include the stimulation conditions in this study (e.g., eiDBS-suppression) as fixed effects with the off-stimulation condition as a reference/control group, and random interc
Conditions Studied
Interventions
- DEVICE Neurostimulation
- DRUG Carbidopa 25/Levodopa 100Mg Tab
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-08-29 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 4 |
What NCT06013956 shows while recruiting
NCT06013956 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Neurostimulation is the first listed.
NCT06013956 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06013956 about?
NCT06013956 is a clinical study titled "Personalized Real-Time DBS and PD Mechanisms". A prospective cohort of patients scheduled to undergo deep brain stimulation (DBS) implantation surgery for the treatment of Parkinson's disease as per standard of care will be invited to participate in this study. This mechanistic study is aimed at better understanding the role of basal ganglia bet...
What is the current status of trial NCT06013956?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2023-08-29. Estimated completion is 2028-06-30.
What conditions does trial NCT06013956 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT06013956?
The interventions under investigation include: Neurostimulation (DEVICE), Carbidopa 25/Levodopa 100Mg Tab (DRUG).
Who is sponsoring clinical trial NCT06013956?
This trial is sponsored by David Escobar, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06013956 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06013956's enrollment target sits among peer trials
25 225th of 297 higher than 67 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease
RECRUITING · Phase 4
-
Cortical Electrophysiology of Response Inhibition in Parkinson's Disease
RECRUITING · Phase 4
-
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
RECRUITING · Phase 4
-
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
-
Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI